Medivir Strengthens Finances and Pipeline as Key Cancer and Bone Programs Advance

Medivir AB ( (SE:MVIR) ) has shared an update.

Medivir reported first-quarter 2026 net turnover of SEK 1 million and an improved EBITDA loss, while ending the period with SEK 149.1 million in cash, strengthened further by a SEK 45 million directed share issue to fund development of MIV-711 in Osteogenesis Imperfecta. Governance changes included a reshaped board with a new chairman and a new CFO, reinforcing leadership as the company scales its pipeline.

Operationally, Medivir is advancing two key value drivers: MIV-711, now backed by U.S. Orphan Drug Designation and a newly formed scientific expert council ahead of a phase 2 proof-of-concept study in Osteogenesis Imperfecta, and fostrox, which is entering the FLEX-HCC randomized trial in second-line liver cancer under strong clinical and investigator interest. Additional upside comes from partner Vetbiolix’s rapid progress with VBX-1000 (MIV-701) in canine periodontitis, where confirmatory data expected in late 2026 could trigger partnering opportunities and future royalty streams for Medivir.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish biopharmaceutical company listed on Nasdaq Stockholm’s Small Cap segment that develops innovative therapies for diseases with high unmet medical need. Its lead drug candidates are fostrox, a precision chemotherapy targeting liver cancer, and MIV-711, aimed at treating Osteogenesis Imperfecta, both considered to have blockbuster potential in sizeable global markets.

Average Trading Volume: 11,322,427

Technical Sentiment Signal: Hold

Current Market Cap: SEK1.03B

See more insights into MVIR stock on TipRanks’ Stock Analysis page.